The immune responsiveness in hepatitis C virus infected patients: Effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells

Luigi Amati, R. Cozzolongo, O. G. Manghisi, R. Cuppone, N. M. Pellegrino, D. Caccavo, E. Jirillo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α/ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand, and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.

Original languageEnglish
Pages (from-to)2093-2100
Number of pages8
JournalCurrent Pharmaceutical Design
Volume10
Issue number17
DOIs
Publication statusPublished - 2004

Fingerprint

Ribavirin
Interferon-alpha
Hepacivirus
Lactoferrin
B-Lymphocytes
Lymphocytes
Lipopolysaccharides
Interferons
Therapeutics
Interleukin-10
Autoantibodies
Antiviral Agents
Anti-Idiotypic Antibodies
Cell Count
Cytokines
Serum

Keywords

  • B lymphocytes
  • Endotoxins
  • Hepatitis C virus
  • Interferon-α
  • Ribavirin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The immune responsiveness in hepatitis C virus infected patients : Effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells. / Amati, Luigi; Cozzolongo, R.; Manghisi, O. G.; Cuppone, R.; Pellegrino, N. M.; Caccavo, D.; Jirillo, E.

In: Current Pharmaceutical Design, Vol. 10, No. 17, 2004, p. 2093-2100.

Research output: Contribution to journalArticle

@article{b30e4a9dfca7420cb640efb9b741fd1e,
title = "The immune responsiveness in hepatitis C virus infected patients: Effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells",
abstract = "Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α/ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand, and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.",
keywords = "B lymphocytes, Endotoxins, Hepatitis C virus, Interferon-α, Ribavirin",
author = "Luigi Amati and R. Cozzolongo and Manghisi, {O. G.} and R. Cuppone and Pellegrino, {N. M.} and D. Caccavo and E. Jirillo",
year = "2004",
doi = "10.2174/1381612043384231",
language = "English",
volume = "10",
pages = "2093--2100",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "17",

}

TY - JOUR

T1 - The immune responsiveness in hepatitis C virus infected patients

T2 - Effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells

AU - Amati, Luigi

AU - Cozzolongo, R.

AU - Manghisi, O. G.

AU - Cuppone, R.

AU - Pellegrino, N. M.

AU - Caccavo, D.

AU - Jirillo, E.

PY - 2004

Y1 - 2004

N2 - Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α/ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand, and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.

AB - Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α/ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand, and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.

KW - B lymphocytes

KW - Endotoxins

KW - Hepatitis C virus

KW - Interferon-α

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=3042555478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042555478&partnerID=8YFLogxK

U2 - 10.2174/1381612043384231

DO - 10.2174/1381612043384231

M3 - Article

C2 - 15279548

AN - SCOPUS:3042555478

VL - 10

SP - 2093

EP - 2100

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 17

ER -